ALT compared with LBRX: revenue, margins and what each company keeps, and the suppliers and customers both name

ALTAltimmune, Inc.

Mkt capRevenueRevenue

LBRXLB Pharmaceuticals Inc

Mkt capRevenueRevenue

Compare

ALTAltimmune, Inc.

LBRXLB Pharmaceuticals Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ALT

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±12.7%▼−2.33%×0.18

May 13 '26±8.2%▼−1.95%×0.23

Q1 FY26±10.3%▼−17.92%×1.74

Q3 FY25±14.3%▲+5.07%×0.36

LBRX

Reportimpliedrealized× implied

Q2 FY26—▼−1.13%—

May 13 '26—▲+3.79%—

Q1 FY26

= impliedALT realized, solidLBRX realized, hatchedOne scale, both sides: full bar = 18%× = |realized| ÷ impliedSource: market data

—

▼−2.81%

—

Q3 FY25—▼−4.26%—

ALTAltimmune, Inc.

2.04▼−4.90%· post 2.07

Mkt cap$396.8MRevenue$26,000Q4 FY25Revenue$41,000FY25

LBRXLB Pharmaceuticals Inc

39.74▼−1.02%· post 41.20

ClosedOct 30 '26

Mkt cap$1.2BRevenue—Revenue—

Compare

ClosedOct 30 '26

ALTAltimmune, Inc.

LBRXLB Pharmaceuticals Inc

2.04▼−4.90%post 2.07

Price

39.74▼−1.02%post 41.20

$396.8M

Mkt cap

$1.2B

Q4 FY25$26,000

Revenue

—

FY25$41,000

Revenue

—

ALT2.04▼−4.90%vsLBRX39.74▼−1.02%ClosedOct 30 '26